RegenxBio's AMD gene therapy well tolerated in Phase I

RegenxBio Inc. (NASDAQ:RGNX) said a single subretinal injection of RGX-314 was well tolerated with no treatment-related serious adverse events reported in a Phase I trial to treat wet age-related

Read the full 296 word article

User Sign In